Starpharma Holdings Limited - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 27 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "Starpharma Holdings Limited - Product Pipeline Review - 2014" provides data on the Starpharma Holdings Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Starpharma Holdings Limited's corporate website, SEC filings, investor presentations and featured press releases, both from Starpharma Holdings Limited and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Starpharma Holdings Limited - Brief Starpharma Holdings Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Starpharma Holdings Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Starpharma Holdings Limited with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Starpharma Holdings Limited's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Starpharma Holdings Limited's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Starpharma Holdings Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Starpharma Holdings Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Starpharma Holdings Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Starpharma Holdings Limited and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Starpharma Holdings Limited Snapshot 4
Starpharma Holdings Limited Overview 4
Key Information 4
Key Facts 4
Starpharma Holdings Limited - Research and Development Overview 5
Key Therapeutic Areas 5
Starpharma Holdings Limited - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Starpharma Holdings Limited - Pipeline Products Glance 9
Starpharma Holdings Limited - Late Stage Pipeline Products 9
Phase III Products/Combination Treatment Modalities 9
Starpharma Holdings Limited - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Starpharma Holdings Limited - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Starpharma Holdings Limited - Drug Profiles 12
astodrimer 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
docetaxel nano formulation 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
doxorubicin dendrimer 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Starpharma Holdings Limited - Pipeline Analysis 16
Starpharma Holdings Limited - Pipeline Products by Therapeutic Class 16
Starpharma Holdings Limited - Pipeline Products by Target 17
Starpharma Holdings Limited - Pipeline Products by Route of Administration 18
Starpharma Holdings Limited - Pipeline Products by Molecule Type 19
Starpharma Holdings Limited - Pipeline Products by Mechanism of Action 20
Starpharma Holdings Limited - Recent Pipeline Updates 21
Starpharma Holdings Limited - Company Statement 24
Starpharma Holdings Limited - Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables
Starpharma Holdings Limited, Key Information 4
Starpharma Holdings Limited, Key Facts 4
Starpharma Holdings Limited - Pipeline by Indication, 2014 6
Starpharma Holdings Limited - Pipeline by Stage of Development, 2014 7
Starpharma Holdings Limited - Monotherapy Products in Pipeline, 2014 8
Starpharma Holdings Limited - Phase III, 2014 9
Starpharma Holdings Limited - Phase II, 2014 10
Starpharma Holdings Limited - Preclinical, 2014 11
Starpharma Holdings Limited - Pipeline by Therapeutic Class, 2014 16
Starpharma Holdings Limited - Pipeline by Target, 2014 17
Starpharma Holdings Limited - Pipeline by Route of Administration, 2014 18
Starpharma Holdings Limited - Pipeline by Molecule Type, 2014 19
Starpharma Holdings Limited - Pipeline Products by Mechanism of Action, 2014 20
Starpharma Holdings Limited - Recent Pipeline Updates, 2014 21
Starpharma Holdings Limited, Subsidiaries 25